Every 8-K that Iovance Biotherapeutics, Inc. (IOVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IOVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IOVA filings page.
Iovance Biotherapeutics, Inc. updated its corporate presentation on August 6, 2026. The materials are used for presentations at healthcare conferences and in meetings with analysts, existing stockholders, and other interested parties.
The updated presentation is provided as Exhibit 99.1 and is incorporated by reference, making its contents part of the company’s public disclosures.
Iovance Biotherapeutics reported record second-quarter 2026 revenue of $99.3 million, up 66% year over year, with roughly $91 million from Amtagvi and gross margin of 56%. Operating loss narrowed to $51.9 million and net loss to $47.3 million, while six-month net loss improved to $126.4 million from $227.8 million.
Management is reviewing its prior 2026 revenue guidance of $350–$370 million and plans to update it in the third quarter. The cash position, including cash, cash equivalents, short-term investments and restricted cash, was about $304 million as of June 30, 2026, which the company expects will fund operations into the second half of 2028.
The update also highlights progress across the TIL pipeline: Fast Track Designation for lifileucel in soft tissue sarcomas, advancing registrational programs in metastatic non-squamous NSCLC and advanced melanoma, next-generation gene-edited and IL-12 tethered TIL therapies, and expanding global Amtagvi access with recent approval in Australia and ongoing reviews in the UK and Switzerland.
Iovance Biotherapeutics, Inc. updated its corporate presentation used for investor and conference meetings, outlining commercial progress, pipeline data, and financial guidance. The company highlights Amtagvi as the first FDA-approved one-time T cell therapy for solid tumors in second-line and later advanced melanoma, with more than 1,500 patients treated across commercial and clinical use.
The presentation reiterates Q2 2026 revenue guidance of $86M–$88M and full-year 2026 revenue guidance of $350M–$370M, supported by cash of about $319M as of March 31, 2026 and stated cash runway into 2028. Iovance reports over 90 authorized treatment centers, more than 200 million covered patient lives, and broad payer coverage generally aligned with clinical data and guidelines.
Clinical data summaries emphasize deep and durable responses in advanced melanoma, early but encouraging results in nonsquamous non-small cell lung cancer and soft tissue sarcomas, and proof-of-concept efforts in endometrial cancer. The company also details next-generation TIL and IL-2/IL-12-based programs intended to enhance efficacy and durability in solid tumors.
Iovance Biotherapeutics reported that stockholders approved all seven proposals at its Annual Meeting, including an amendment to the 2020 Employee Stock Purchase Plan adding 1,000,000 shares and an increase in authorized common stock from 500,000,000 to 650,000,000 shares. Directors were re-elected, executive compensation received advisory approval, and Ernst & Young LLP was ratified as auditor.
The company also received marketing authorization from Australia’s Therapeutic Goods Administration for Amtagvi (lifileucel) to treat previously treated advanced melanoma. Amtagvi is described as the first T cell therapy for a solid tumor cancer and the first option in Australia for advanced melanoma after anti-PD-1 and targeted therapy.
Iovance Biotherapeutics reported first quarter 2026 revenue of about $71.4 million, approximately 45% higher than a year earlier, reflecting strong demand for Amtagvi. The company issued revenue guidance of $86–88 million for the second quarter and $350–370 million for full-year 2026, signaling expectations for continued growth.
Iovance remains unprofitable, with a net loss of $79.0 million and a loss per share of $0.19, though both improved versus 2025. Management highlighted internal manufacturing efficiencies, cost reductions, and a 40% confirmed objective response rate in metastatic serous endometrial cancer as it advances multiple TIL therapy trials. Cash, cash equivalents, and investments totaled $313.4 million as of March 31, 2026.
Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company’s annual meeting of stockholders, which is anticipated to be held in June 2026.
Ms. Yarno will continue to serve as a director until the annual meeting. The company stated that her decision to retire is not due to any disagreement with Iovance regarding its operations, policies, or practices, and publicly thanked her for her service on the Board.
Iovance Biotherapeutics reported strong topline growth for the fourth quarter and full year 2025 while remaining loss-making as it scales commercialization of Amtagvi. Fourth-quarter product revenue reached $86.8M, up from $73.7M a year earlier, contributing to full-year 2025 revenue of $263.5M versus $164.1M in 2024, meeting its $250M–$300M guidance range. Q4 gross margin improved to 50%, but total 2025 costs and expenses of $666.9M led to a net loss of $391.0M, or $(1.09) per share. Cash, cash equivalents and investments were $297.0M as of December 31, 2025, with an investor presentation indicating total cash of about $303M and runway into Q3 2027. Strategically, growth is driven by increasing Amtagvi demand in advanced melanoma, while the pipeline advanced with a U.S. FDA Fast Track designation for lifileucel in second-line advanced non-small cell lung cancer and multiple ongoing registrational and proof-of-concept trials in solid tumors.
Iovance Biotherapeutics, Inc. filed a report describing an updated corporate presentation it will use with healthcare conference audiences, analysts, current stockholders, and others. In that presentation, the company states it expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of sales for its therapy Amtagvi. The updated slide deck is provided as Exhibit 99.1 to the report.
Iovance Biotherapeutics filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025 and recent updates. The press release is included as Exhibit 99.1.
The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL.
Iovance Biotherapeutics, Inc. (IOVA) submitted an 8-K reporting other events and provided a corporate presentation as an exhibit. The filing lists written and soliciting communications under Rule 425 and Rule 14a-12, plus pre-commencement communications under Rules 14d-2(b) and 13e-4(c). The disclosure includes Exhibit 99.1, a corporate presentation dated August 29, 2025, and an Inline XBRL cover page. The document is signed by Frederick G. Vogt, Ph.D., J.D. in his capacity as Interim CEO, President, and General Counsel.
Iovance Biotherapeutics, Inc. filed an 8-K reporting written and soliciting communications under several securities rules and that it has engaged Jefferies to use commercially reasonable efforts to sell the company’s common shares from time to time under customary trading parameters. The filing references pre-commencement and solicitation rules and states the communication is dated August 22, 2025. The 8-K is signed by Frederick G. Vogt, Ph.D., J.D., Interim CEO and President, and General Counsel.
Iovance Biotherapeutics reported that Health Canada has approved its therapy Amtagvi (lifileucel) for patients with advanced melanoma who have already received anti-PD-1 and targeted therapies. This gives Canadian patients a new treatment option after other standard treatments have failed. The company shared this news through a press release, which is attached as an exhibit to the report.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) filed a Form 8-K announcing the recruitment of Corleen Roche as Chief Financial Officer, effective August 6, 2025.
The Executive Employment Agreement, signed July 7, 2025, replaces current Principal Financial Officer Matthew W. Rosinack. Roche will receive an annual base salary of $600,000, a $50,000 one-time sign-on bonus, and is eligible for an annual discretionary bonus up to 45 % of salary.
Equity incentives under the 2018 Equity Incentive Plan comprise (i) an option to purchase 300,000 shares at the closing price on the effective date, vesting one-third after 12 months and quarterly thereafter, and (ii) 150,000 restricted stock units with identical vesting cadence. Unvested awards forfeit upon termination except where severance conditions are met.
Severance terms for a termination without cause include: (1) salary continuation for 12 months, (2) pro-rated bonus, (3) immediate vesting of unvested equity, and (4) continuation of applicable benefits. Enhanced protection applies upon a change-of-control event.
Professional background: Roche, 59, has served as CFO of CG Oncology (2024-present), Immunome (2021-2023), and Biogen U.S. (2019-2021), following senior finance roles at Sandoz and Wyeth. She began her career at PwC and holds a B.A. in Accountancy from Villanova University.
The Company issued a press release (Exhibit 99.1) on July 15, 2025 to publicly announce the appointment.